NCCTG to Conduct Phase II Study of Cell Therapeutics' Brostallicin in Metastatic Triple Negative Breast Cancer

News   Apr 29, 2010

 
NCCTG to Conduct Phase II Study of Cell Therapeutics' Brostallicin in Metastatic Triple Negative Breast Cancer
 
 
 

RELATED ARTICLES

Cancer Cells’ Energy Source Blocked by Natural Compound

News

Researchers have not only untangled an unusual wiring system that cancer cells use for carbohydrate metabolism, but also identified a natural compound that appears to selectively shut down this system in laboratory studies.

READ MORE

The Ancient Behaviour of Sleep, Conserved Throughout Evolution

News

The finding that jellyfish sleep implies that sleep is an ancient behavior, largely untouched by millennia of evolution.

READ MORE

Trispecific Antibodies Protect Against HIV

News

A three-pronged antibody made in the laboratory protected monkeys from infection with two strains of SHIV, a monkey form of HIV, better than individual natural antibodies from which the engineered antibody is derived.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Diagnostics Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE